Advances diabetes and obesity programs with icovamenib demonstrating durable 52-Week Phase II data and with BMF-650, Biomea’s next-generation, oral small molecule glucagon-like peptide-1 (“GLP-1”) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback